SEC Form 4 · accession 0001209191-19-008693
PUMA BIOTECHNOLOGY, INC. · PBYI
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Steven Lo
Officer — Chief Commercial Officer
Period of report
Feb 6, 2019
Accepted (ET)
Feb 8, 2019 · 5:39 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001401667
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| STOCK OPTION (RIGHT TO BUY)F1 | $27.76 | Feb 6, 2019 | A | 36,300 | A | — | Feb 5, 2029 | COMMON STOCK | 36,300 | 36,300 | D |
Explanation of responses
- F1The vesting commencement date ("Option Vesting Commencement Date") of the option is January 1, 2019. The option vests (i) with respect to one-third (1/3rd) of the shares underlying the option on the first anniversary of the Option Vesting Commencement Date and (ii) with respect to 1/36th of the shares underlying the option on each monthly anniversary of the Option Vesting Commencement Date thereafter, subject to the Reporting Person's continued service with the Issuer through the applicable vesting date.